Overall, these data indicate that inhibiting WDR5, or its target TGFβ1, is an effective strategy to sensitize drug-resistant cells to chemotherapy, as found for ZEB1, TWIST, and SNAIL [50–52], thus suggesting a rational combination to restrict BC progression. The gene discussed is ZEB1; the disease is breast cancer.